Entera BioENTX
Market Cap: $73.7M
About: Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Employees: 19
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
37% more capital invested
Capital invested by funds: $7.11M [Q1] → $9.75M (+$2.63M) [Q2]
2.77% more ownership
Funds ownership: 12.01% [Q1] → 14.78% (+2.77%) [Q2]
0% more funds holding
Funds holding: 15 [Q1] → 15 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 117 / 274 met price target | 393%upside $10 | Buy Reiterated | 12 Aug 2024 |